You may have seen recent headlines that people living with obesity will be able to begin accessing tirzepatide (Mounjaro) for weight loss purposes in primary care settings. This does not mean prescriptions will be provided immediately. It means primary care settings can begin discussions with patients about whether tirzepatide is the right option to improve their health through weight loss.
In Hampshire and the Isle of Wight around 1,000 people currently qualify for the medication based on national eligibility criteria – the ICB are working to set up services quickly however this will not be available locally until later this year (Autumn) – so please don’t contact the surgery just yet, as we will be unable to help currently.
Full qualifying criteria is a BMI of 40 or greater and FOUR or MORE of the following diagnosed health conditions:
- type 2 diabetes
- Hypertension
- Cardiovascular disease
- Obstructive sleep apnoea
- Dyslipidaemia
For more information: